Sign In
Buy BNTC
$11.71
-0.150 (-1.26%)
At Close: Jul 31, 2026
Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer
11:51pm, Tuesday, 15'th Apr 2025
We initiate a Buy rating for Benitec Biopharma due to promising early data from BB 301 for OPMD and a cash runway into mid-2027. BB 301 shows potential for meaningful improvements in swallowing functi
Insiders Are Loving These 5 Tech and Biotech Stocks
08:45am, Wednesday, 02'nd Apr 2025
After struggling through a rough patch, the biotech industry seems to be staging a comeback.
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
08:00am, Tuesday, 25'th Mar 2025
HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing
Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
10:55am, Thursday, 20'th Feb 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable,
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable
09:50am, Thursday, 20'th Feb 2025
Benitec Biopharma (BNTC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thro
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
08:10am, Friday, 14'th Feb 2025
-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dy
Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock
10:51am, Monday, 13'th Jan 2025
Benitec Biopharma (BNTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why
09:51am, Wednesday, 25'th Dec 2024
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?
10:56am, Monday, 09'th Dec 2024
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 113.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why
09:50am, Monday, 09'th Dec 2024
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Benitec Biopharma to Participate in Upcoming Investor Conferences in December
07:00am, Tuesday, 26'th Nov 2024
HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
04:30pm, Thursday, 14'th Nov 2024
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clini
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
08:00am, Monday, 04'th Nov 2024
HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing
Benitec Biopharma: OPMD Program Continues To Advance With Catalysts
03:35pm, Thursday, 17'th Oct 2024
Benitec Biopharma Inc.'s BB-301 showed positive interim results in treating OPMD, allowing for higher dosing in 2025 and a potential late-stage trial in 2026. BB-301 demonstrated significant improveme
Benitec Biopharma Announces Updated Investor Webcast Information
06:00am, Monday, 14'th Oct 2024
-Management plans to host an investor webcast on October 14 th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below-
